This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple institutions conducted a randomized controlled trial to assess the immunogenicity of a recombinant acellular pertussis vaccine (r-aP) that included genetically detoxified pertussis toxin (PT) and filamentous hemagglutinin (FHA), compared to that of a licensed acellular pertussis (aP) vaccine with chemically detoxified PT (cd/Tdap) in previously immunized adolescents. Healthy adolescents, 11–15 years old, from the Geneva, Switzerland area who had received 5 previous aP immunizations were randomized to receive either r-aP and tetanus-diphtheria (Td) vaccines or cd/Tdap. Blood was obtained at baseline and at 28 and 365 days after immunization for measurement of anti-PT neutralizing antibodies, and PT, FHA, tetanus toxoid (TT), and diphtheria toxoid (DT) specific immunoglobulin (IgG) antibodies. The primary outcome was …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.